LDN-193189 (DM-3189)

Description: LDN-193189 (also called LDN193189; DM-3189; DM3189) is a highly potent and selective small molecule inhibitor of the BMP (bone morphogenetic protein) signaling pathway with potential antineoplastic activity. It inhibits the transcriptional activity of the BMP type I receptor kinases such as ALK2 (activin receptor-like kinase-2) and ALK3 with IC50s of 5 nM and 30 nM in C2C12 cells, respectively. LDN-193189 exhibits 200-fold selectivity for BMP over TGF-beta. LDN-193189 also exhibits the inhibitory effects on associated vascular inflammation, osteogenic activity, and calcification.

References: Nat Med. 2008 Dec; 14(12):1363-9; Br J Pharmacol. 2010 Sep; 161(1):140-9.

Related CAS #: 1062368-24-4 (free base) 2310134-98-4 or 1062368-62-0 (4HCl) 1435934-00-1 (dihydrochloride)

DM3189; LDN193189; DM-3189; LDN 193189; DM 3189; LDN-193189

Chemical Name: 4-[6-(4-Piperazin-1-yl-phenyl)-pyrazolo[1, 5-a]pyrimidin-3-yl]-quinoline

SMILES Code: C1(C2=C3N=CC(C4=CC=C(N5CCNCC5)C=C4)=CN3N=C2)=CC=NC6=CC=CC=C16

Exact Mass: 406.19059